Hypothesis

Core claim: Adaptive NAD+ decline becomes pathogenic when a mitochondrial‑nuclear NAD+/NADH ratio threshold persistently activates ATM‑dependent chromatin relaxation at NF‑κB target loci, driving a SIRT6‑deficient inflammatory state that further consumes NAD+. Restoring NAD+ in bursts while transiently boosting nuclear SIRT6 activity resets the ratio without overriding the adaptive downregulation program.

Mechanistic Rationale

• The Treebak study showed that 85% skeletal‑muscle NAD+ loss does not accelerate frailty, indicating the tissue can tolerate low NAD+ when the drop is static and coordinated ([1]).
• However, low NAD+ reduces SIRT6 deacetylase activity, leading to hyperacetylation of H3K9 at promoters of IL‑1β, NLRP3 and cGAS‑STING genes ([2][3]).
• Hyperacetylated chromatin increases transcriptional noise and NF‑κB binding, raising inflammatory cytokine output; cytokine signaling activates CD38 and PARP1, which hydrolyze NAD+, closing a positive feedback loop ([4]).
• We propose that the loop is gated by a mitochondrial‑nuclear redox checkpoint: when the mitochondrial NAD+/NADH ratio falls below ~0.2, ATM is autophosphorylated, phosphorylates H2AX, and relaxes nucleosome positioning at NF‑κB sites, making them SIRT6‑sensitive. This checkpoint is absent in the Treebak model because the NAD+ decline is chronic but steady, keeping the ratio above the threshold; acute fluctuations (e.g., from high‑fat diet or senescence‑associated secretory phenotype) push the ratio below threshold, triggering the loop.

Novel Intervention Design

1. Intermittent NAD+ bolus – administer nicotinamide riboside (NR) or NMN in 6‑hour pulses every 48 h to raise cytosolic NAD+ without sustaining high levels that would suppress the adaptive downregulation signal ([1]).
2. Compartment‑specific SIRT6 activator – use a mitochondrially‑targeted SIRT6‑activating compound (e.g., a MD‑SIRT6 agonist) that preferentially accumulates in the nucleus after mitochondrial import, boosting deacetylase activity only during the NAD+ pulse window.
3. Epigenetic monitoring – track the EpiAge‑R Repair Capacity Index (RCI) alongside a NAD+ flux assay (e.g., extracellular NAD+ turnover measured by LC‑MS) to confirm that adaptive decline (stable low NAD+ with high RCI) is preserved while the inflammaging loop (low RCI, high H3K9ac at NF‑κB loci) is reversed.

Testable Predictions

• Prediction 1: In aged mice receiving pulsed NR + nuclear‑targeted SIRT6 activator, serum IL‑6 and TNF‑α will drop ≥30% compared with continuous NR or vehicle, while muscle NAD+ remains ~15‑20% of young levels.
• Prediction 2: H3K9ac at the NLRP3 promoter will decrease significantly only in the pulse group, correlating with restored SIRT6 activity (measured by a fluorometric deacetylase assay) and unchanged PGC‑1α expression (indicating preserved mitochondrial adaptive signaling).
• Prediction 3: EpiAge‑R RCI will improve (increase by ≥0.15 units) in the pulse group, whereas epigenetic age acceleration (DNAm GrimAge) will show no further decline, demonstrating uncoupling of damage from pace.
• Prediction 4: If the mitochondrial‑nuclear redox checkpoint is genetically disrupted (ATM‑KO in muscle), pulsed NAD+ alone will fail to reduce inflammation, confirming the checkpoint’s necessity.

Falsifiability

• Failure to observe reduced inflammatory cytokines despite successful NAD+ pulses and nuclear SIRT6 activation would falsify the claim that the loop is driven by SIRT6‑dependent chromatin relaxation.
• Persistent elevation of H3K9ac at NF‑κB targets despite the intervention would indicate that additional acetyltransferases (e.g., p300) dominate the response, refuting the SIRT6‑centric mechanism.
• No change in EpiAge‑R RCI while NAD+ flux normalizes would suggest that the adaptive‑damage distinction captured by the clock is not linked to the proposed loop, requiring alternative explanations.

References

[1] https://cbmr.ku.dk/news/2025/time-to-bin-your-supplements-low-levels-of-nad-may-not-drive-aging/ [2] https://www.nad.com/news/longevity-interventions-age-related-dna-modifications [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12402629/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC12940517/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC11830421/ [6] https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1558735/full